Sepsis-associated Thrombocytopenia and Platelet Transfusion (STAPT)
Key facts
- Who runs it
- Nanfang Hospital, Southern Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- 15 Nov 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- SAT patients
- Record updated
- 30 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients admitted to the ICU between January 2021 and May 2024 and subsequently discharged
- Age ≥ 18 years
- Meeting the Sepsis-3.0 diagnostic criteria
- Platelet count < 100 × 10⁹/L at ICU admission
- ICU length of stay ≥ 48 hours
Who cannot take part
- Receipt of chemotherapy, immunosuppressants (e.g., cyclosporine, rituximab), or hematopoietic stem cell/solid organ transplantation within 2 weeks
- Active bleeding (e.g., major gastrointestinal bleeding, intracranial hemorrhage) or hematologic malignancies (e.g., leukemia, myelodysplastic syndrome, lymphoma)
- Liver cirrhosis (Child-Pugh class B/C), chronic kidney disease (CKD stage 4-5), or autoimmune diseases (e.g., systemic lupus erythematosus)
- Pre-existing chronic thrombocytopenia (baseline platelet count <100×10⁹/L for >1 month) or long-term use of antiplatelet/anticoagulant drugs (>2 weeks)
- Significant baseline coagulation dysfunction at ICU admission:Prothrombin time (PT) >1.5 times the upper limit of normal; Activated partial thromboplastin time (APTT) >1.5 times the upper limit of normal; Fibrinogen level <1.0 g/L
- Missing >20% of key data (e.g., daily platelet counts, ICU survival status within 28 days)
- Pregnancy or lactation
- APACHE II score ≥30 within 24 hours of ICU admission
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.
The 2 groups in the trial
- Platelet Transfusion Group
Platelet Transfusion within 14 days after ICU admission
Treatment: SAT patients
- No Platelet Transfusion Group
No Platelet Transfusion within 14 days after ICU admission
Treatment: SAT patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of Platelet Transfusion Therapy on 28-day Mortality in Septic Patients With Thrombocytopenia During ICU Stay: a Multicenter Retrospective Observational Study
- Record updated
- 30 January 2026